Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in
combination with radiation therapy as a possible treatment for recurrent or metastatic
gynecologic cancer.
The names of the immunotherapy drugs involved in this study are:
- Durvalumab
- Tremelimumab